These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

87 related items for PubMed ID: 3976729

  • 1. In vivo alteration of a mutant human protein using the free thiol cysteamine.
    Gahl WA, Gregg RE, Hoeg JM, Fisher E.
    Am J Med Genet; 1985 Feb; 20(2):409-17. PubMed ID: 3976729
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [Cysteamine in the treatment of cystinosis in children. In vitro and in vivo studies].
    Louis JJ, Guibaud P, Dumoulin R, Parchoux B, Zabot MT, Bureau J, Baltassat P, Frederich A, Larbre F.
    Pediatrie; 1984 Dec; 39(8):619-33. PubMed ID: 6535971
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Treatment of cystinosis using cysteamine].
    Broyer M, Tete MJ.
    Ann Pediatr (Paris); 1990 Feb; 37(2):91-3. PubMed ID: 2321906
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Identification of variant apolipoprotein E by isoelectric focusing and restriction isotyping in a patient with type III hyperlipoproteinemia.
    Nassar BA, McPherson R, Lamothe EM, al-Sultan AI, Zhang ZJ, Rosenblatt DS.
    Clin Chem; 1991 Jul; 37(7):1308. PubMed ID: 1677318
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Nephropathic cystinosis: effect of long-term cysteamine therapy.
    Proesmans W, Baten E, Hoogmartens J, Bruyneel P.
    Clin Nephrol; 1987 Jun; 27(6):309-12. PubMed ID: 3608256
    [Abstract] [Full Text] [Related]

  • 14. Restriction isotyping of apolipoprotein E R145C in type III hyperlipoproteinemia.
    Hsia SH, Connelly PW, Hegele RA.
    J Investig Med; 1995 Apr; 43(2):187-94. PubMed ID: 7735921
    [Abstract] [Full Text] [Related]

  • 15. New mutants of apolipoprotein E associated with atherosclerotic diseases but not to type III hyperlipoproteinemia.
    Yamamura T, Yamamoto A, Sumiyoshi T, Hiramori K, Nishioeda Y, Nambu S.
    J Clin Invest; 1984 Oct; 74(4):1229-37. PubMed ID: 6480826
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Treatment of cystinosis with cysteamine. A pilot study determining dose and form of application.
    Bergonzi E, Herren A, Lavanchy P, Bühlmann C, Wyss SR, Lüthy C, Oetliker O.
    Helv Paediatr Acta; 1981 Nov; 36(5):437-43. PubMed ID: 7031022
    [Abstract] [Full Text] [Related]

  • 18. [Apolipoprotein E phenotyping--useful in the study of hyperlipoproteinemia type III].
    Hagve TA, Furuset T, Christophersen B, Ose L.
    Tidsskr Nor Laegeforen; 1993 Mar 10; 113(7):853-6. PubMed ID: 8480294
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Unusual xanthomas in a young patient with heterozygous familial hypercholesterolemia and type III hyperlipoproteinemia.
    Feussner G, Dobmeyer J, Nissen H, Hansen TS.
    Am J Med Genet; 1996 Oct 16; 65(2):149-54. PubMed ID: 8911609
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.